Annovis Bio, Inc.
ANVS · NYSE
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 6.80 | 0.03 | 0.05 | -0.02 |
| FCF Yield | -12,074.91% | -44,323.12% | -11.94% | -3.06% |
| EV / EBITDA | 2,747.24 | 0.63 | -8.74 | -20.95 |
| Quality | ||||
| ROIC | -0.04% | -25.93% | -67.05% | -48.92% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.48 | 0.82 | 1.46 | 1.41 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 36.96% | -97,652.88% | -158.81% | 5.15% |
| Safety | ||||
| Net Debt / EBITDA | 2,754.04 | 3.54 | 1.57 | 2.88 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -8.37 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |